-
公开(公告)号：US20090182008A1
公开(公告)日：2009-07-16
申请号：US12331086
申请日：2008-12-09
IPC分类号： A61K31/47 , C07D215/02
CPC分类号： C07D215/14 , C07B2200/13
摘要： The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译： 本发明涉及匹伐他汀半钙盐的新结晶形式，下文称为多晶型A，B，C，D，E和F，以及无定形形式。 此外，本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定形形式和药物组合物。
-
公开(公告)号：US20090281162A1
公开(公告)日：2009-11-12
申请号：US12386413
申请日：2009-04-17
IPC分类号： A61K31/40 , C07D207/34
CPC分类号： C07D207/34
摘要： The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
-
公开(公告)号：US20120101126A1
公开(公告)日：2012-04-26
申请号：US13280431
申请日：2011-10-25
IPC分类号： A61K31/47 , C07D215/14
CPC分类号： C07D215/14 , C07B2200/13
摘要： The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译： 本发明涉及匹伐他汀半钙盐的新结晶形式，以下称为多晶型A，B，C，D，E和F，以及无定形形式。 此外，本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定形形式和药物组合物。
-
公开(公告)号：US07538136B2
公开(公告)日：2009-05-26
申请号：US10130197
申请日：2001-12-19
IPC分类号： A61K31/40 , C07D207/325
CPC分类号： C07D207/34
摘要： The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
摘要翻译： 本发明涉及阿托伐他汀钙（2:1）的新结晶形式，以下称为多晶型X，A，B1，B2，C，D和E.此外，本发明涉及制备方法 的这些结晶形式和包含结晶形式的药物组合物。
-
公开(公告)号：US20080269315A1
公开(公告)日：2008-10-30
申请号：US12080141
申请日：2008-03-31
IPC分类号： A61K31/40 , C07D207/30
CPC分类号： C07D207/34
摘要： The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.
摘要翻译： 本发明涉及阿托伐他汀钙的新型多晶型F，其制备方法和包含该结晶形式的药物组合物。
-
公开(公告)号：US20080249149A1
公开(公告)日：2008-10-09
申请号：US10585448
申请日：2005-01-05
申请人： Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
发明人： Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
IPC分类号： A61K31/41 , C07D249/08 , A61P25/06 , A61K31/135
CPC分类号： C07D403/06
摘要： The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.
摘要翻译： 本发明涉及利多曲坦苯甲酸酯的新型多晶型A和B型，其制备方法和包含这些结晶形式的药物组合物。
-
公开(公告)号：US20080194604A1
公开(公告)日：2008-08-14
申请号：US11883008
申请日：2006-01-23
IPC分类号： A61K31/505 , C07D239/42
CPC分类号： C07D239/42
摘要： Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.
摘要翻译： 双[（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基）氨基]嘧啶-5-基] - （3R，5S）-3,5-二羟基庚-6- - 烯酸]（也称为瑞舒伐他汀）钙盐和水合物可以以新的晶型B和C存在。这些晶体形式在结晶材料上提供更高的多样性以优化制造，配制和生物效率。
-
公开(公告)号：US07932387B2
公开(公告)日：2011-04-26
申请号：US11883008
申请日：2006-01-23
IPC分类号： C07D239/42 , A61K31/505 , A61P3/06
CPC分类号： C07D239/42
摘要： Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.
摘要翻译： 双[（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基）氨基]嘧啶-5-基] - （3R，5S）-3,5-二羟基庚-6- - 烯酸]（也称为瑞舒伐他汀）钙盐和水合物可以以新的晶型B和C存在。这些晶体形式在结晶材料上提供更高的多样性以优化制造，配制和生物效率。
-
公开(公告)号：US07777049B2
公开(公告)日：2010-08-17
申请号：US10585448
申请日：2005-01-05
申请人： Paul Adriaan Van Der Schaaf , Jörg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
发明人： Paul Adriaan Van Der Schaaf , Jörg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
IPC分类号： C07D401/12
CPC分类号： C07D403/06
摘要： The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.
摘要翻译： 本发明涉及利多曲坦苯甲酸酯的新型多晶型A和B型，其制备方法和包含这些结晶形式的药物组合物。
-
公开(公告)号：US07432380B2
公开(公告)日：2008-10-07
申请号：US10576784
申请日：2004-10-06
IPC分类号： C07D209/12
CPC分类号： C07D209/24
摘要： A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compositions comprising this crystalline form are reported.
摘要翻译： 描述了氟伐他汀钠水合物的新型结晶形式，下文称为多晶型G.此外，报道了制备该结晶形式的方法和包含该结晶形式的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.028 秒)
